U.S. Patent 6,432,440: Claim Scope, Expiration, Patent Landscape, and Generic Entry Risk

U.S. Patent 6,432,440 covers liquid mucosal pharmaceutical compositions that use low-esterification pectin to form a gel at the administration site without adding an external divalent-metal-ion solution. Its principal protection is technology-based rather than drug-specific. The patent reaches nasal, vaginal, rectal, oral-throat, and ophthalmic delivery systems, along with related kits, treatment methods, delivery methods, and manufacturing processes.

The patent is no longer a live U.S. exclusion right. It was issued on August 13, 2002, and its ordinary term has expired by 2026 under either the pre-1995 17-year-from-grant regime or the post-1995 20-year-from-earliest-effective-filing regime, subject to any unusual patent-term adjustment, disclaimer, or extension shown in the prosecution record. The patent does not create current U.S. generic-entry risk by itself.

What technology does U.S. Patent 6,432,440 protect?

The patent protects a mucoadhesive or in situ gelling delivery platform based on pectin having a low degree of esterification.

The central technical combination is:

A therapeutic agent.
Pectin with a degree of esterification below 50%, or, in some claims, pectin described as having a “low degree of esterification.”
An aqueous carrier.
Administration to a mucosal surface.
Gelation at, or adaptation to gel at, the application site.
Gelation without an extraneously applied source of divalent metal ions.

The absence of external divalent metal ions is a central limitation. The claims are directed to formulations that can gel through conditions present at the mucosal site, including endogenous ions, local pH, concentration changes, dehydration, or other site-specific mechanisms described in the patent specification.

The patent is not limited to a single active ingredient, disease, dosage strength, or commercial product. Its value was therefore greatest as a platform patent covering formulation architecture.

How many independent claims does the patent contain?

The supplied claims contain six principal independent claim groups:

Claim	Claim category	Core subject matter
1	Composition	Liquid mucosal composition containing low-esterification pectin
18	Kit	Composition and kit without an externally supplied divalent-metal-ion solution
20	Product-by-process composition	Gel formed after application of the liquid composition to mucosa
21	Treatment method	Treatment or prophylaxis using the composition
23	Delivery method	Delivery of therapeutic agents to mammalian mucosa
24	Manufacturing process	Mixing therapeutic agent, pectin, and aqueous carrier

Claim 1 is the broadest composition claim. Claims 18, 20, 21, 23, and 24 extend protection to commercial packaging, the administered gel state, therapeutic use, delivery activity, and preparation of the formulation.

What are the essential limitations of claim 1?

Claim 1 requires every element below:

Element	Scope implication
“Liquid pharmaceutical composition”	The product must be liquid before administration
“For administration to a mucosal surface”	The intended route must involve mucosa
“Therapeutic agent”	A non-therapeutic cosmetic or industrial pectin product is outside the claim
Pectin with degree of esterification below 50%	High-methoxyl pectin at or above 50% is outside the literal limitation
Aqueous carrier	Non-aqueous systems are outside the claim
Gels or is adapted to gel at the application site	The formulation must possess site-specific gelling functionality
Absence of extraneous divalent metal ions	A separately applied calcium, magnesium, or comparable ion solution can defeat literal infringement

The composition must satisfy the limitations at the time of manufacture or sale. A product can fall within the claim even if gelation occurs only after contact with mucosal fluid, provided the formulation is “adapted to gel” at the site.

The claim does not expressly require:

A particular pectin source.
A particular therapeutic agent.
A specific gelation time.
A specified viscosity.
A specific molecular weight.
A specific pH, except where claim 9 is asserted.
A particular delivery device.
A particular mucosal disease.
A defined level of mucoadhesion.
External calcium or another gelling trigger.

How do the dependent claims narrow the patent scope?

Claims 2 through 17 add route, dosage-form, concentration, pH, and therapeutic-agent limitations.

Claims	Limitation
2	Nasal cavity
3	Vagina
4	Rectum
5	Back of throat
6	Eye
7	Spray or liquid free-flowing system
8	Pectin concentration of 1 to 100 g/L
9	pH between 2 and 9
10	Antiviral agent for nasal or vaginal delivery
11	Vaccine for nasal, rectal, or vaginal delivery
12	Decongestant
13	Contraceptive
14	Vaginal lubricant
15	Anti-allergic agent
16	Pharmaceutically acceptable dosage form
17	Spray or liquid free-flowing dosage form

The dependent claims create narrower positions that may be easier to practice but generally have less commercial breadth. Claims 10 through 15 are particularly relevant to product-specific enforcement because they tie the formulation to therapeutic categories.

What formulations are protected by the patent?

The patent can reach formulations such as:

Nasal sprays that remain liquid during dispensing and gel after contacting nasal mucosa.
Vaginal liquid contraceptive or antiviral formulations.
Vaginal lubricants containing low-esterification pectin.
Rectal vaccine or therapeutic-agent delivery systems.
Oropharyngeal sprays or liquids designed to gel on the back of the throat.
Ophthalmic liquids that gel after application to the eye.
Decongestant and anti-allergic mucosal formulations.
Kits containing the liquid formulation and instructions, where the kit excludes a separately supplied divalent-ion solution.

The patent does not require that the formulation be a spray. A dropper, applicator, pump, syringe, or other liquid-delivery device may fall within the claims if the remaining limitations are satisfied.

How does the “absence of extraneous divalent metal ions” limitation affect infringement?

This limitation is both a boundary and a potential design-around.

A product is less likely to fall within the literal scope of claim 1 if it requires the user or healthcare provider to apply a separate calcium, magnesium, or other divalent-metal-ion solution to the mucosal surface before or after administration.

The analysis becomes more difficult where:

The formulation itself contains calcium or magnesium.
The formulation contains a divalent ion that is not supplied as a separate solution.
The formulation gels through endogenous mucosal ions.
The formulation uses a cationic polymer or another gelation mechanism.
A device releases the formulation and a second agent simultaneously.
The product’s instructions require a separate pretreatment step.

The claim language focuses on an “extraneous source” applied to the mucosal surface. An internally incorporated ion source may not automatically satisfy or avoid the limitation. The result depends on claim construction, the specification, prosecution history, and the factual role of the ion in gelation.

What is the scope of the kit claims?

Claims 18 and 19 cover a kit containing:

A liquid pharmaceutical composition.
A therapeutic agent.
Low-esterification pectin.
An aqueous carrier.
A formulation that gels or is adapted to gel at the administration site.
No solution of divalent metal ions intended to be added externally.
Under claim 19, instructions to administer without an external divalent-ion source.

The kit claims could have been relevant to commercial packaging even where the formulation alone was difficult to characterize. They also create an issue for induced infringement analysis because written instructions can establish the intended manner of use.

The exclusion of a divalent-ion solution is unusual in commercial-kit terms. A kit that includes calcium chloride, magnesium chloride, or another external gelling solution may avoid the literal wording of claims 18 and 19, although it could raise separate questions under the composition or method claims.

What protection do claims 20 through 24 provide?

Claim 20: administered gel composition

Claim 20 covers the gel composition obtained by applying the liquid formulation to mammalian mucosa. It is a product-by-process-style claim. The claim focuses on the resulting gel and the process by which the gel is formed.

The principal enforcement issue is whether the product can be identified by structural or functional characteristics independent of the application process. Product-by-process claims are generally assessed based on the product itself, not merely the manufacturing steps, although the exact treatment depends on claim construction and applicable precedent.

Claims 21 and 23: treatment and delivery methods

Claim 21 covers treatment or prophylaxis of disease. Claim 23 covers delivery of a therapeutic agent to mammalian mucosa.

These claims require performance of the administration step. They are potentially relevant to direct infringement by a manufacturer only where the manufacturer performs the claimed method or induces another party to perform it. A product label, instructions, promotional materials, and intended use can become relevant to induced-infringement analysis.

The claims are not limited to a particular disease. Their breadth is constrained by the requirement that the therapeutic agent be effective against the disease in claim 21.

Claim 24: preparation process

Claim 24 covers mixing:

The therapeutic agent.
Low-esterification pectin.
The aqueous carrier.

The resulting product must be a liquid composition that gels or is adapted to gel at a mucosal site without an externally applied divalent-ion solution.

This claim is most relevant to manufacturers and contract manufacturers. A process using preformed pectin stock, staged addition, homogenization, or separate premixes may still infringe if the process performs the required mixing steps.

When did U.S. Patent 6,432,440 lose exclusivity?

Event	Date or status
Patent issued	August 13, 2002
Subject matter	Pectin-based mucosal pharmaceutical delivery
Ordinary U.S. patent term	Expired by 2026
Current enforceability	No ordinary enforceable patent term remains
Hatch-Waxman exclusivity	No drug-specific exclusivity created by this patent
Current Paragraph IV threat	None based solely on this expired patent

The exact historical expiration date depends on the patent’s effective filing date and whether any patent-term adjustment, disclaimer, or other term modification applied. The practical conclusion is unchanged: the patent is expired and cannot presently block a U.S. generic, reformulation, or competing mucosal-delivery product.

A patent expiration does not erase historical infringement exposure for acts occurring before expiration. It also does not eliminate possible rights in continuation, divisional, foreign, or later improvement patents.

What is the Orange Book status of U.S. Patent 6,432,440?

The patent is not inherently an Orange Book patent because it is not directed to a named active ingredient, approved strength, dosage form, or specific drug product.

Orange Book listing depends on whether an approved drug sponsor submitted the patent for an approved product and whether the patent met FDA listing requirements. Platform formulation patents can be listed in some circumstances, but a patent covering a broad class of pectin mucosal compositions does not automatically appear in the Orange Book.

The supplied claims do not identify:

An approved drug.
A New Drug Application.
A specific active ingredient.
A trade name.
A dosage strength.
An approved indication.

Accordingly, no product-specific Orange Book or Paragraph IV conclusion follows from the patent claims alone. Even if historically listed against an approved product, expiration would remove the patent as a current barrier to ANDA approval.

Does the patent create Paragraph IV or biosimilar risk?

Paragraph IV risk

Paragraph IV certification is relevant to an ANDA applicant challenging a listed patent for a small-molecule drug. This patent is technology-oriented and does not identify a particular active ingredient. It would therefore be unlikely to create a standalone Paragraph IV filing unless listed against an approved product using the claimed formulation.

Because the patent has expired, it does not create current Paragraph IV launch delay risk under Hatch-Waxman.

Biosimilar risk

Biosimilar procedures under section 351(k) apply to biological products. U.S. Patent 6,432,440 covers a delivery composition and mucosal administration method, not a biologic molecule or biologic manufacturing process. It does not create a biosimilar patent thicket by itself.

A biologic delivered through a pectin-containing mucosal formulation could implicate separate formulation or method patents, but those rights would need to be identified independently.

How strong is the patent estate from a claim-construction perspective?

The patent had meaningful breadth but several potential vulnerability points.

Issue	Effect on claim strength
Low degree of esterification	Clear numerical limit in several claims, improving definition
“Low degree of esterification”	Less precise in claims 18, 21, and 23
“Gels or is adapted to gel”	Broad functional language, but potentially vulnerable to indefiniteness or enablement challenges
Mucosal surface	Broad route coverage
No extraneous divalent ions	Strong distinguishing limitation but also a design-around route
Therapeutic agent	Very broad, supporting platform coverage
pH and concentration	Narrow dependent claims provide fallback positions
Product-by-process claim 20	Potentially complex infringement analysis
Method claims	Require performance or inducement of administration
Process claim 24	Useful against manufacturers but limited to specified mixing activity

The strongest literal claim is likely claim 1 because it combines a defined pectin parameter with broad therapeutic-agent and mucosal-site language. Claims 8 and 9 add objective concentration and pH ranges. Claims 10 through 15 may be commercially useful where a product falls within a specified therapeutic category.

The principal validity pressure points would have included written description and enablement across the full range of therapeutic agents and mucosal sites, clarity of “adapted to gel,” and the technical meaning of gelation in the absence of an extraneous divalent-ion source. Any historical validity assessment would require the prosecution record and prior-art file history.

What competing patent technologies are closest to this estate?

The relevant landscape is divided into five technology groups:

Technology group	Relationship to U.S. 6,432,440
Calcium-triggered low-methoxyl pectin gels	Closest technical field; external-ion requirement may distinguish them
Thermosensitive nasal and vaginal gels	Potentially competing delivery platforms using temperature-triggered polymers
Carbomer and polyacrylic-acid mucoadhesive gels	Competing mucoadhesive chemistry, generally outside the pectin limitation
Cellulose-based in situ gels	Competing aqueous delivery systems using cellulose derivatives
Alginate and polysaccharide gels	Adjacent polysaccharide technology with overlapping mucosal applications

The key freedom-to-operate distinction is whether the formulation contains low-esterification pectin and gels at mucosa without an externally applied divalent-ion solution. A product using poloxamer, carbomer, hydroxypropyl methylcellulose, xanthan gum, alginate, or another non-pectin polymer may avoid literal infringement of claim 1, subject to any later patent family covering that alternative technology.

What licensing deals and litigation affect the patent?

The patent number and supplied claims do not establish a current licensing transaction, settlement agreement, or active U.S. litigation matter. No current enforcement consequence can be assigned to the expired patent without a specific party, product, continuation patent, or court docket.

Historical commercial relevance would have depended on whether the patent owner licensed:

Nasal pectin delivery.
Vaginal contraceptive or antiviral formulations.
Pectin-based ophthalmic gels.
Vaccine delivery systems.
Contract manufacturing or formulation technology.

A license to the expired patent would not, by itself, grant rights to later patents, foreign counterparts, know-how, trademarks, regulatory data, or continuation applications.

What generic launch scenarios exist?

Because the patent is expired, a current entrant can generally pursue the following strategies without waiting for U.S. patent expiration:

Use low-esterification pectin and rely on endogenous mucosal conditions for gelation.
Use a different gelling polymer.
Use external calcium or magnesium if clinically and commercially acceptable.
Avoid one or more dependent-claim ranges, such as the 1 to 100 g/L concentration or pH 2 to 9.
Select a non-mucosal route.
Develop a product-specific formulation that does not contain pectin.
File an ANDA, 505(b)(2) application, or other appropriate application without this expired patent creating a current patent stay.

The remaining risks are likely to arise from later patents covering a particular active ingredient, formulation, device, indication, manufacturing process, or delivery platform rather than from U.S. Patent 6,432,440.

Key Takeaways

U.S. Patent 6,432,440 covers low-esterification pectin liquid formulations that gel on mucosal surfaces without an externally applied divalent-metal-ion solution.
Claim 1 is the principal composition claim and is broad across therapeutic agents and mucosal routes.
Claims 18 through 24 extend protection to kits, administered gels, treatment methods, delivery methods, and manufacturing processes.
The patent is expired by 2026 and does not create current U.S. generic-entry or biosimilar risk.
The absence of an extraneous divalent-ion source is both a key claim limitation and a potential design-around.
The patent is not inherently an Orange Book patent and does not identify a specific approved drug.
Current freedom-to-operate analysis should focus on later continuation patents, product-specific formulation patents, device patents, active-ingredient patents, and foreign rights.

FAQs About U.S. Patent 6,432,440

Can a nasal spray using low-methoxyl pectin still be marketed in the United States?

Yes. This expired patent does not independently prevent commercialization. The product must still comply with applicable FDA requirements and avoid infringement of any later unexpired patent.

Does calcium inside the formulation avoid the patent claims?

Not automatically. The claims focus on the absence of an extraneous divalent-metal-ion source applied to the mucosal surface. Calcium incorporated into the formulation requires a claim-specific analysis.

Does the patent cover pectin-based eye drops?

Claim 6 expressly identifies the eye as a covered mucosal surface. The formulation must also satisfy the independent claim limitations, including low-esterification pectin, an aqueous carrier, therapeutic use, and site-specific gelation.

Could a vaccine delivered vaginally or rectally have been covered?

Yes. Claim 11 expressly covers a vaccine delivered to the nose, rectum, or vagina, provided the composition satisfies claim 1.

Is a pectin-free thermosensitive gel likely to infringe this patent?

A pectin-free formulation is outside the literal requirement for pectin. It may still implicate separate patents covering the alternative polymer, active ingredient, device, indication, or manufacturing process.

References

U.S. Patent No. 6,432,440. (2002). Pectin-based pharmaceutical compositions. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure. U.S. Department of Commerce.
35 U.S.C. §§ 154, 156, 271, 282. (2024). United States Code.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 355, 355(j), 355(k), 355(l). (2024). United States Code.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9707934	Apr 18, 1997

PCT Information
PCT Filed	April 20, 1998	PCT Application Number:	PCT/GB98/01147
PCT Publication Date:	October 29, 1998	PCT Publication Number:	WO98/47535

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0975367	⤷ Start Trial	122011000009	Germany	⤷ Start Trial
Austria	262925	⤷ Start Trial
Australia	7064798	⤷ Start Trial
Australia	741847	⤷ Start Trial
Canada	2282506	⤷ Start Trial
Germany	122011000009	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,432,440

Summary for Patent: 6,432,440